Baricitinib Treatment Increases Eyebrow and Eyelash ​Regrowth Up to ​52 Weeks

Main Article Content

Arash Mostaghimi
Brigham and Women's Hospital, Boston, USA

Melissa Piliang
Cleveland Clinic Foundation, Cleveland, USA

Charles Lynde
The Lynde Institute of Dermatology, Markham, Canada

Jacek C. Szepietowski
Wroclaw Medical University, Wroclaw, Poland

Jakub P. Jedynak
Eli Lilly and Company, ​ Indianapolis, USA

Najwa Somani
Eli Lilly and Company, ​ Indianapolis, USA

Na Lu
Precision Statistics Consulting, Woodbury, USA

Guanglei Yu
Eli Lilly and Company, ​ Indianapolis, USA

Chiara Chiasserini
Eli Lilly and Company, ​ Indianapolis, USA

Maria Hordinsky
University of Minnesota Medical School, Minneapolis, USA

Keywords

Baricitinib

References

1. Mesinkovska N, et al. J Investig Dermatol Symp Proc. 2020;20:S62-S68. ​

2. Pratt CH, et al. Nat Rev Dis Primers. 2017;3:17011. ​

3. Kwon O, et al. Am J Clin Dermatol. 2023;24:443-451.​

4. Aldhouse NVJ, et al. J Patient Rep Outcomes. 2020;4:76.​

5. Nguyen B, et al. Am J Clin Dermatol. 2023;24:55-67.​

6. Wyrwich KW, et al. Am J Clin Dermatol. 2020;21:725-732.​

7. Sadr J, et al. Perception. 2003;32:285-293

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.297

Article Details

How to Cite
[1]
Mostaghimi, A. , Piliang, M. , Lynde, C. , Szepietowski, J.C. , Jedynak, J.P. , Somani, N. , Lu, N. , Yu, G. , Chiasserini, C. and Hordinsky, M. 2023. Baricitinib Treatment Increases Eyebrow and Eyelash ​Regrowth Up to ​52 Weeks. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s297. DOI:https://doi.org/10.25251/skin.7.supp.297.
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2 3 4 5 > >>